Article
Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Aging - 8 Jan 2024
Hung Ling-Jen, Hsu Ping-Chih, Yang Cheng-Ta, Kuo Chih-Hsi Scott, Chang John Wen-Cheng, Huang Chen-Yang, Chang Ching-Fu, Wu Chiao-En
Abstract excerpt
BACKGROUND: In real-world practice, most patients with lung cancer are diagnosed when they are aged ≥65 years. However, clinical trials tend to lack data for the elderly population. Therefore, we aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.